Pulsed field ablation with a variable loop circular catheter in atrial fibrillation: Acute outcomes from the VARIPURE multicenter study
Alexandre Almorad, F. Sébag, M. B. Kronborg, Christian Sohns et autres
0 citationsHeart Rhythm
Katie Steenackers
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
12Publications signalées
474Citations signalées
0Affiliations récentes
Domaines associés
Respiratory viral infections researchSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCystic Fibrosis Research AdvancesPediatric health and respiratory diseases
Publications récentes
Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial
Katie Steenackers, Nikita Hanning, Liesbeth Bruckers, Isabelle Desombere et autres
4 citationsVaccine
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Michael G. Ison, Alberto Papi, Eugene Athan, Robert G. Feldman et autres
174 citationsClinical Infectious Diseases
Humoral Immune Response Against SARS-CoV-2 after Adapted Covid-19 Vaccine Schedules in Healthy Adults: The IMCOVAS Study
Katie Steenackers, Nikita Hanning, Liesbeth Bruckers, Isabelle Desombere et autres
0 citationsSSRN Electronic Journal
EFICÁCIA DE UMA VACINA DE PROTEÍNA F PRÉ-FUSÃO DO VÍRUS SINCICIAL RESPIRATÓRIO (RSVPREF3 OA) EM ADULTOS MAIS VELHOS COM CONDIÇÕES CARDIORRESPIRATÓRIAS COEXISTENTES
Lessandra Michelin, Veronica Hulstrøm, Alberto Papi, Robert G. Feldman et autres
0 citationsThe Brazilian Journal of Infectious Diseases
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions
Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers, Dong‐Gun Lee et autres
55 citationsClinical Infectious Diseases
Late Breaking Abstract - Efficacy of a respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults with co-existing cardiorespiratory conditions
Alberto Papi, Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers et autres
3 citations
280-LB: Efficacy of a Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults with Preexisting Medical Conditions
Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers, Dong‐Gun Lee et autres
6 citationsDiabetes
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study
Silvia Narejos Pérez, Josep Ramón, Airi Põder, Isabel Leroux‐Roels et autres
19 citationsOpen Forum Infectious Diseases
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
Isabel Leroux‐Roels, Matthew Davis, Katie Steenackers, Brandon Essink et autres
124 citationsThe Journal of Infectious Diseases
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
Ilse De Coster, Isabel Leroux‐Roels, Ananda S Bandyopadhyay, Christopher Gast et autres
85 citationsThe Lancet
119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated
Jelena Tica, Javier Ruiz Guiñazú, Charles P. Andrews, Matthew Davis et autres
4 citationsOpen Forum Infectious Diseases
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.